US Stem Cell Inc
OTC:USRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
National Grid PLC
OTC:NGGTF
|
UK |
|
Marijuana Inc
OTC:MAJI
|
US |
|
C
|
China National Building Material Co Ltd
SWB:D1Y
|
CN |
US Stem Cell Inc
Total Liabilities
US Stem Cell Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
US Stem Cell Inc
OTC:USRM
|
Total Liabilities
$14.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
0%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$81.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
US Stem Cell Inc
Glance View
U.S.Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc. is a biotechnology company that is focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of disease and injury. Its MyoCell and MyoCell SDF-1 product candidates are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. Its Adipocell product is a cell therapy with a range of treatment applications using autologous adipose cells. The firm's business includes the development of cell therapy products, distribution of regenerative medicine products, as well as physician and patient-based regenerative medicine/cell therapy training services. The firm operates through its US Stem Cell Training, Inc. (SCT) and Vet biologics (VBI) divisions.
See Also
What is US Stem Cell Inc's Total Liabilities?
Total Liabilities
14.8m
USD
Based on the financial report for Dec 31, 2022, US Stem Cell Inc's Total Liabilities amounts to 14.8m USD.
What is US Stem Cell Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
0%
Over the last year, the Total Liabilities growth was 16%. The average annual Total Liabilities growth rates for US Stem Cell Inc have been 16% over the past three years , 11% over the past five years .
